Precipio, Inc. (PRPO)

Over the past six months, Precipio, Inc. announced a Q4 and Year-End 2025 Shareholder Update Call and the publication of a joint study with Memorial Sloan-Kettering Cancer Center. The company reported 2025 revenues grew to $24.0M, a 30% increase year-over-year, and took steps towards a clean balance sheet. Precipio showcased its BCR::ABL1 panel at the 2025 ASH Meeting and reported unauthorized access to isolated storage with no operational impact. The company announced Q3-2025 financial results and the termination of a sales agreement with A.G.P./Alliance Global Partners. Precipio reported strong Q1 2025 revenue growth and FY 2025 financial results, including a GAAP EPS of -$0.23 and revenues of $24.05 million, with an Adjusted EBITDA of $1.23 million. The 2025 annual report included a going-concern warning due to an operating loss and accumulated deficit.

Precipio, Inc. experiences demand seasonality, with the first quarter typically seeing a seasonal dip in revenues due to the reset of insurance plans. Management anticipates a rebound in the second quarter, with a return to positive cash flow from operations by Q2 or Q3.

Precipio, Inc. is a healthcare biotechnology company focused on improving cancer diagnostics, particularly in hematologic malignancies. The company develops and commercializes technologies that integrate molecular diagnostics with specialized laboratory services, encompassing both diagnostic testing services and the sale of diagnostic tools. Its major products include IV-Cell, a cell culture media; HemeScreen, a suite of genetic diagnostic panels; diagnostic blood cancer testing services; and biomarker testing and clinical project services.

Precipio, Inc. is headquartered in the United States, with CLIA laboratories in New Haven, Connecticut, and Omaha, Nebraska. Its customer base is concentrated in North America, serving U.S. hospitals, clinics, and pathology practices. While its diagnostic products are designed for global applicability, its revenue-generating activities are tied to U.S. operations.

Precipio's brand reputation has seen mixed signals, with Wall Street Zen upgrading Precipio to a "buy" rating and Weiss Ratings reaffirming a "sell" rating. MarketBeat data indicates an average rating of "Sell" from analysts. The unauthorized access to isolated storage and the auditor's going-concern warning could negatively impact investor confidence and brand reputation.

The ownership structure of Precipio (PRPO) stock includes institutional investors (3.40% to 6.51%), insiders (11.21%), and retail investors (around 82.27%). Major institutional owners include AMH Equity Ltd, Topline Capital Management, LLC, BlackRock, Inc., and Vanguard Group Inc. Ilan Danieli, the CEO, owns a significant number of shares.